0001209191-23-001286.txt : 20230104
0001209191-23-001286.hdr.sgml : 20230104
20230104180018
ACCESSION NUMBER: 0001209191-23-001286
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230101
FILED AS OF DATE: 20230104
DATE AS OF CHANGE: 20230104
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HUNT RONALD
CENTRAL INDEX KEY: 0001247851
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38503
FILM NUMBER: 23508551
MAIL ADDRESS:
STREET 1: C/O CREDIT SUISSE 1ST BOSTON PRV EQY
STREET 2: 11 MADISON AVENUE
CITY: NEW YORK
STATE: NY
ZIP: 10010
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Iterum Therapeutics plc
CENTRAL INDEX KEY: 0001659323
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: FITZWILLIAM COURT, 1ST FLOOR
STREET 2: LEESON CLOSE
CITY: DUBLIN 2
STATE: L2
ZIP: D02 YW24
BUSINESS PHONE: (872) 225-6077
MAIL ADDRESS:
STREET 1: FITZWILLIAM COURT, 1ST FLOOR
STREET 2: LEESON CLOSE
CITY: DUBLIN 2
STATE: L2
ZIP: D02 YW24
FORMER COMPANY:
FORMER CONFORMED NAME: Iterum Therapeutics Ltd
DATE OF NAME CHANGE: 20151124
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-01
0
0001659323
Iterum Therapeutics plc
ITRM
0001247851
HUNT RONALD
C/O ITERUM THERAPEUTICS PLC
FITZWILLIAM COURT, FL. 1, LEESON CLOSE
DUBLIN 2
L2
IRELAND
1
0
0
0
Ordinary Shares
2023-01-01
4
M
0
1197
A
4030
D
Ordinary Shares
71445
I
By New Leaf Ventures III, L.P.
Ordinary Shares
25641
I
By New Leaf Biopharma Opportunities II, L.P.
Restricted Share Units
0.00
2023-01-01
4
M
0
1197
0.00
D
Ordinary Shares
1197
0
D
Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.
On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported on this Form 4 have been adjusted to reflect the Reverse Share Split.
These shares are held directly by New Leaf Ventures III, L.P. ("NLV-III"). New Leaf Venture Associates III, L.P. ("NLVA-III LP") is the general partner of NLV-III and New Leaf Venture Management III, L.L.C. ("NLVM-III LLC") is the general partner of NLVA-III LP, and each of NLVA-III LP and NLVM-III LLC may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NLV-III. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NLVM-III LLC and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NLV-III. The reporting person disclaims Section 16 beneficial ownership of the securities held by NLV-III, except to the extent of his pecuniary interest therein, if any.
These shares are held directly by New Leaf Biopharma Opportunities II, L.P. ("NBPO-II"). New Leaf BPO Associates II, L.P. ("NBPO-IIA") is the general partner of NBPO-II and New Leaf BPO Management II, L.L.C. ("NBPO-IIM") is the general partner of NBPO-IIA, and each of NBPO-IIA and NBPO-IIM may be deemed to have sole voting, investment and dispositive power with respect to the shares held by NBPO-II. The reporting person, a member of the Issuer's Board of Directors, is a managing director of NBPO-IIM and, in his capacity as a managing director, may be deemed to have shared voting, investment and dispositive power with respect to the shares held by NBPO-II. The reporting person disclaims Section 16 beneficial ownership of the securities held by NBPO-II, except to the extent of his pecuniary interest therein, if any.
On March 25, 2022, the reporting person was granted an award of 17,955 RSUs (the "RSU Grant"), which vested on January 1, 2023.
The number of ordinary shares underlying the RSU Grant have been adjusted to reflect the Reverse Share Split.
/s/ Ronald M. Hunt
2023-01-04